Publications by authors named "Pradeep Shahi"
Article Synopsis
- Nanomedicines are special tiny medicines that can do many jobs, but scientists still don't understand how they work very well, which makes it hard to use them in real-life treatments.
- To make better nanomedicines, researchers are screening different designs to find the best ones to use in patients.
- They created predictions and a model to compare and improve similar products, helping to make sure new medicines work like the original ones do.
Purpose: To compare the pharmacokinetic bioequivalence and safety of a generic pegylated liposomal doxorubicin formulation (SPIL DXR hydrochloride liposome injection) with that of the reference products, Caelyx or Doxil.
Methods: Two open-label, two-way reference crossover studies were conducted in patients with ovarian cancer. C, AUC, and AUC, V, and Cl for total, free, and encapsulated DXR were evaluated in 18 blood samples taken pre-dose (t = 0), at increasing time intervals over the following 14 days.
A novel corticosteroid compound (short form of IUPAC name: SFDAC) has been discovered by Sun Pharma Advanced Research Company (SPARC) Ltd. A randomized, observer-blind, active-controlled, parallel-groups, intranasal multiple escalating dose study was conducted in healthy male subjects to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of compound SFDAC formulated as an aqueous suspension for intranasal administration. Intranasal sprays of SFDAC, active control fluticasone propionate (FP) and placebo were administered once in a day for 14 days as per randomization.
View Article and Find Full Text PDF